MariMed Earnings Call: Wholesale Strength Amid Margin Squeeze

Marimed ((MRMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

MariMed’s latest earnings call struck a cautiously optimistic tone as management balanced solid brand momentum with clear profitability pressures. Executives highlighted resilient wholesale and retail performance, disciplined cost control, and improved balance sheet flexibility, but also acknowledged margin compression, weaker results in mature retail markets, and a still‑thin cash cushion.

Full-Year Revenue Growth and Q4 Performance

MariMed reported full‑year 2025 revenue of roughly $159.8–$160.0 million, describing the outcome as modest growth versus 2024 despite some internal debate over whether it equated to about 1% or closer to 7%. Fourth‑quarter revenue reached $41.7 million, up 1.3% sequentially, underscoring steady but unspectacular top‑line momentum in a challenging pricing environment.

Sixth Straight Year of Positive Adjusted EBITDA

The company logged its sixth consecutive year of positive adjusted EBITDA, posting $16.9 million for 2025 and an EBITDA margin of 10.5%. That profitability streak is a key differentiator in cannabis, even though management conceded that margins came under pressure and EBITDA declined year over year.

Wholesale Expansion Drives Revenue Mix Shift

Wholesale was a standout, with aggregate channel revenue growing 11% in 2025 and rising to 44% of total sales from 40% a year earlier. Management framed this shift as central to the strategy, with new market entries such as Illinois and Delaware contributing meaningfully to the broader wholesale growth story.

Retail Momentum and Loyalty-Fueled Engagement

On the retail side, Q4 2025 revenue grew 4% sequentially, a sharp reversal from a 5% drop in the same quarter a year earlier, as transactions increased 4% sequentially and 8% year over year. MariMed’s Thrive loyalty program continued to scale, with membership up 7% sequentially and 31% annually, supported by the launch of a new Thrive app aimed at personalized marketing and lower customer acquisition costs.

Category Leadership and Delaware Adult-Use Surge

MariMed emphasized its brand strength, noting Betty’s Eddies as the number‑one edible in its markets and Vibations holding the number‑four spot in ready‑to‑drink beverages. Following Delaware’s adult‑use launch, wholesale revenue in the state jumped 37% sequentially and management claims number‑one overall market share there, while sales at its two Delaware stores rose roughly 1.25 times after the transition.

Rapid Illinois Wholesale Scale-Up

In Illinois, where MariMed began wholesale distribution only two years ago, revenue in that channel climbed 39% year over year. The company expanded into 27 additional dispensaries during 2025, closing the year with about 82% penetration across Illinois retailers, underscoring the scalability of its asset‑light model in newer territories.

High Store Penetration Across Core Markets

Across its footprint, MariMed products were sold into roughly 85% of retail stores, a gain of about 200 basis points year over year. Massachusetts penetration reached about 83% of dispensaries and Maryland was nearly fully covered at 108 out of 109 stores, giving the company broad shelf presence even in markets facing intensifying price competition.

Cost Discipline and Liquidity Management

Operating expenses were tightly controlled, rising only about 0.7% year over year to $56.9 million, reflecting disciplined SG&A management. The company also restructured its preferred shares to extend maturities, lifted cash and equivalents to $8.9 million from $7.3 million, and reported no material near‑term debt maturities, improving financial flexibility despite a higher interest burden.

Profitability Headwinds and Earnings Declines

Despite cost discipline, profitability slipped, with non‑GAAP EBITDA down roughly 12.8% year over year as lower gross profit and one‑time impacts weighed on results. Operating income fell to $8.8 million from $11.4 million in 2024, and fourth‑quarter operating income was $2.4 million, down about $667,000 sequentially, signaling near‑term pressure on earnings.

Gross Margin Compression in a Competitive Landscape

Non‑GAAP gross margin declined modestly to about 40% in the fourth quarter as intense pricing pressure in mature markets eroded unit economics. Management stressed that operational efficiencies partially offset these headwinds, but the margin trend underlines how competitive dynamics are squeezing even relatively efficient operators.

Retail Challenges in Illinois and Core Market Pricing

Retail performance was mixed, with Illinois particularly challenged as retail revenue there fell 26% year over year despite strong wholesale gains, and management expects ongoing price compression in 2026. In Massachusetts, steady retail revenue masked underlying weakness, as sustained pricing pressure drove down average order values even as transaction counts increased.

Missouri Exit and Its Impact on Results

MariMed’s exit from Missouri in October 2025 followed a period in which those operations delivered a negative contribution to earnings. Management acknowledged that this underperforming market materially dragged on full‑year profitability, reinforcing the company’s focus on pruning assets that lack a clear path to acceptable returns.

Q4 Wholesale Softness Highlights Market Volatility

While the wholesale channel expanded for the year, fourth‑quarter wholesale revenue slipped to $17.6 million from $18.0 million in the prior quarter. This sequential dip, driven by price pressure in mature states, underscored the volatility of bulk sales and the importance of continued brand differentiation and disciplined account management.

Thin Cash Cushion and Higher Interest Costs

Cash on hand at year‑end, though improved to $8.9 million, remains modest relative to industry cyclicality and potential regulatory shifts. The preferred‑share refinancing that stabilized the balance sheet also carries a cost, with management flagging an estimated $800,000 annual increase in interest expense that will weigh on future net income.

Uncertain Timing for New Market Contributions

MariMed is investing in early‑stage initiatives in Pennsylvania and New York, but executives warned that these opportunities will not be quick fixes for earnings. The New York processing facility is under construction with revenue expected only in late 2026 or early 2027, while Pennsylvania licensing and approvals could take one to two years before meaningfully contributing.

Guidance and Outlook: Wholesale, Delaware, and Ohio in Focus

Looking ahead to 2026, management expects growth to be driven primarily by further wholesale penetration, a full‑year lift from Delaware’s adult‑use market, and contributions from a new dispensary in Columbus, Ohio. The company also plans to accelerate Thrive loyalty engagement and bring more MariMed brands in‑house to support margins, while remaining cautious on the timing of revenue from Pennsylvania and New York.

MariMed’s earnings call painted a picture of a cannabis operator with strong brands, expanding wholesale reach, and disciplined costs, but one that is still wrestling with pricing pressure and limited liquidity. For investors, the story hinges on whether wholesale growth, Delaware’s adult‑use tailwind, and new Ohio retail can offset margin compression and fund the next leg of expansion until new markets finally come online.